Asbestos.com this week published an article about the NIPU trial in which Ultimovacs’ universal cancer vaccine UV1 will be investigated in a randomized, multi-center phase II trial in advanced malignant pleural mesothelioma (MPM). The article includes an interview with our Chief Medical Officer, Jens Bjørheim. The NIPU trial investigates UV1 in combination with the checkpoint inhibitors nivolumab and ipilimumab as second-line treatment in mesothelioma. Oslo University Hospital (‘OUS’) is the sponsor of the study. Bristol-Myers Squibb (‘BMS’) and Ultimovacs have entered into agreements with OUS to support the preparations and execution of the trial. The full article can be accessed here (18.09.2020)
Article in Asbestos.com on the NIPU trial
News
Second quarter 2020 results held on Friday 21 August 2020. Please see the presentation section for webcast and report.
Technology
Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.
Clinical studies
Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.